{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:15:20Z","timestamp":1785104120245,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7759\/cureus.108061","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:24:02Z","timestamp":1777598642000},"source":"Crossref","is-referenced-by-count":2,"title":["Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report"],"prefix":"10.7759","author":[{"given":"Edward","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.06.25323524","article-title":"Monitoring report: GLP-1 RA prescribing trends: June 2025 data","author":"Gratzl S","year":"2025","unstructured":"Gratzl S, Cartwright BM, Rodriguez PJ, Gilbert K, Do D, Masters N, Stucky NL. Monitoring report: GLP-1 RA prescribing trends: June 2025 data. medRXiv. 2025, 10.1101\/2025.03.06.25323524","journal-title":"medRXiv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)02105-1","article-title":"GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck MA","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026, 407:892-908. 10.1016\/s0140-6736(25)02105-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review","volume":"19","author":"Liu Z","year":"2025","unstructured":"Liu Z, Yu S, Jin X, et al.. The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review. Drug Des Devel Ther. 2025, 19:10383-409. 10.2147\/DDDT.S559919","journal-title":"Drug Des Devel Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker MD","year":"2022","unstructured":"Walker MD, Shane E. Hypercalcemia: a review. JAMA. 2022, 328:1624-36. 10.1001\/jama.2022.18331","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164896","article-title":"Beyond glycemic control: GLP-1 receptor agonists and their impact on calcium homeostasis in real-world patients","volume":"13","author":"Alenezi BT","year":"2024","unstructured":"Alenezi BT, Elfezzani N, Uddin R, et al.. Beyond glycemic control: GLP-1 receptor agonists and their impact on calcium homeostasis in real-world patients. J Clin Med. 2024, 13:4896. 10.3390\/jcm13164896","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-25-0067","article-title":"A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use","volume":"2025","author":"Nduma B","year":"2025","unstructured":"Nduma B, Malapati SN, Vibhuti V. A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use. Endocrinol Diabetes Metab Case Rep. 2025, 2025:10.1530\/EDM-25-0067","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1681\/asn.20213210s1148a","article-title":"Liraglutide-induced hypercalcemia with AKI","volume":"32","author":"Patel N","year":"2021","unstructured":"Patel N, Shahzad MA, Whittier WL. Liraglutide-induced hypercalcemia with AKI. J Am Soc Nephrol. 2021, 32:148. 10.1681\/asn.20213210s1148a","journal-title":"J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2004.04.006","article-title":"Electrocardiographic manifestations: electrolyte abnormalities","volume":"27","author":"Diercks DB","year":"2004","unstructured":"Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004, 27:153-60. 10.1016\/j.jemermed.2004.04.006","journal-title":"J Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1956","article-title":"No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial","volume":"41","author":"Heged\u00fcs L","year":"2018","unstructured":"Heged\u00fcs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsb\u00f8l JD, Daniels GH. No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial. Diabetes Care. 2018, 41:620-2. 10.2337\/dc17-1956","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697442","article-title":"The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment","volume":"12","author":"Xie B","year":"2021","unstructured":"Xie B, Chen S, Xu Y, et al.. The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Front Pharmacol. 2021, 12:697442. 10.3389\/fphar.2021.697442","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020600","article-title":"The role of glucose-dependent insulinotropic polypeptide (GIP) in bone metabolism","volume":"27","author":"Lin A","year":"2026","unstructured":"Lin A, Kitaura H, Ohori F, et al.. The role of glucose-dependent insulinotropic polypeptide (GIP) in bone metabolism. Int J Mol Sci. 2026, 27:600. 10.3390\/ijms27020600","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.261","article-title":"Milk-alkali syndrome","volume":"84","author":"Medarov BI","year":"2009","unstructured":"Medarov BI. Milk-alkali syndrome. Mayo Clin Proc. 2009, 84:261-7. 10.4065\/84.3.261","journal-title":"Mayo Clin Proc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.12.016","article-title":"Metabolic alkalosis pathogenesis, diagnosis, and treatment: Core Curriculum 2022","volume":"80","author":"Do C","year":"2022","unstructured":"Do C, Vasquez PC, Soleimani M. Metabolic alkalosis pathogenesis, diagnosis, and treatment: Core Curriculum 2022. Am J Kidney Dis. 2022, 80:536-51. 10.1053\/j.ajkd.2021.12.016","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.06.004","article-title":"Pathophysiology of metabolic alkalosis: a new classification based on the centrality of stimulated collecting duct ion transport","volume":"58","author":"Gennari FJ","year":"2011","unstructured":"Gennari FJ. Pathophysiology of metabolic alkalosis: a new classification based on the centrality of stimulated collecting duct ion transport. Am J Kidney Dis. 2011, 58:626-36. 10.1053\/j.ajkd.2011.06.004","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.04.006","article-title":"Acid-base and potassium homeostasis","volume":"33","author":"Lee Hamm L","year":"2013","unstructured":"Lee Hamm L, Hering-Smith KS, Nakhoul NL. Acid-base and potassium homeostasis. Semin Nephrol. 2013, 33:257-64. 10.1016\/j.semnephrol.2013.04.006","journal-title":"Semin Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482020-hypercalcemia-induced-by-tirzepatide-and-calcium-supplementation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:24:03Z","timestamp":1777598643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482020-hypercalcemia-induced-by-tirzepatide-and-calcium-supplementation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.108061","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}